Visual hallucinations (VHs) are common in patients with Parkinson disease (PD), especially those with dementia, whereas auditory hallucinations are quite rare. Recent studies have revealed the involvement of several regions along the visual information-processing system that contribute to the pathophysiological mechanism of VHs: the eyes and retina, retinofugal projection, lateral geniculate nucleus, striate cortex, ventral pathways in the temporal cortices, and frontal and parietal cortices. In addition, the concurrent involvement of other systems in the brainstem and basal forebrain further modify VHs in PD. In this review, we discuss the pathophysiological association between the regional involvement of these areas and VHs.
FénelonGMahieuxFHuonRZiéglerM.Hallucinations in Parkinson’s disease. Prevalence, phenomenology and risk factors. Brain. 2000;123(pt 4):733–745.
3.
PapapetropoulosSArgyriouAAEllulJ. Factors associated with drug-induced visual hallucinations in Parkinson’s disease. J Neurol. 2005;252(10):1223–1228.
4.
FénelonGSoulasTZenasniFCleret de LangavantL. The changing face of Parkinson’s disease-associated psychosis: a cross-sectional study based on the new NINDS-NIMH criteria. Mov Disord. 2010;25(6):763–766. doi:10.1002/mds22839.
5.
McKeithIGBoeveBFDicksonDW, et al.Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89(1):88–100.
HallidayGHelyMReidWMorrisJ. The progression of pathology in longitudinally followed patients with Parkinson’s disease. Acta Neuropathol. 2008;115(4):409–415.
8.
GoetzCGStebbinsGTOuyangB. Visual plus nonvisual hallucinations in Parkinson’s disease: development and evolution over 10 years. Mov Disord. 2011;26(12):2196–2200. doi:10.1002/mds.23835.
9.
MosimannUPRowanENPartingtonCE, et al.Characteristics of visual hallucinations in Parkinson disease dementia and dementia with Lewy bodies. Am J Geriatr Psychiatry. 2006;14(2):153–160.
10.
GoetzCGStebbinsGT. Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology. 1993;43(11):2227–2229.
11.
MerimsDShabtaiHKorczynADPeretzCWeizmanNGiladiN. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson’s disease. J Neural Transm. 2004;111(10-11):1447–1453.
12.
Doé do MaindrevilleAFénelonGMahieuxF. Hallucinations in Parkinson’s disease: a follow-up study. Mov Disord. 2005;20(2):212–217.
13.
AarslandDLarsenJPCummingsJLLaakeK. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease. A community-based study. Arch Neurol. 1999;56(5):595–601.
14.
GoetzCGPappertEJBlasucciLM, et al.Intravenous levodopa in hallucinating Parkinson’s disease patients: high-dose challenge does not precipitate hallucinations. Neurology. 1998;50(2):515–517.
15.
FénelonGGoetzCGKarenbergA. Hallucinations in Parkinson disease in the prelevodopa era. Neurology. 2006;66(1):93–98.
16.
PagonabarrageJMartinez-HortaSde BobadillaRF, et al.Minor hallucinations occur in drug-naïve Parkinson’s disease patients, even from the premotor phase. Mov Disord. 2016;31(1):45–52.
17.
HolroydSCurrieLWootenGF. Prospective study of hallucinations and delusions in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2001;70(6):734–738.
18.
MatsuiHUdakaFTamuraA, et al.Impaired visual acuity as a risk factor for visual hallucinations in Parkinson’s disease. J Geriatr Psychiatry Neurol. 2006;19(1):36–40.
19.
MosimannUPMatherGWesnesKAO’BrienJTBurnDJMcKeithIG. Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology. 2004;63(11):2091–2096.
20.
MeppelinkAMKoertzJBorgMLeendersKLvan LaarT. Visual object recognition and attention in Parkinson’s disease patients with visual hallucinations. Mov Disord. 2008;23(13):1906–1912.
21.
NaimarkDJacksonERockwellEJesteDP. Psychotic symptoms in Parkinson’s disease patients with dementia. J Am Geratr Soc. 1996;44(33):296–299.
22.
KleinCKömpfDPulkowskiUMoserAViereggeP. A study of visual hallucinations in patients with Parkinson’s disease. J Neurol. 1997;244(6):371–377.
23.
KuritaAMurakamiMTakagiSMatsushimaMSuzukiM. Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies. Mov Disord. 2010;25(2):167–171.
24.
ArchibaldNKClarkeMPMossimannUDBurnDJ. The retina in Parkinson’s disease. Brain. 2009;132(pt 5):1128–1145.
25.
LeeJ-YKimJMAhnJKimH-JJeonBSKimTW. Retinal nerve fiber layer thickness and visual hallucinations in Parkinson’s disease. Mov Disord. 2014;29(1):61–67.
26.
BüttnerTKuhnWMüllerT, et al.Visual hallucinosis: the major clinical determinant of distorted chromatic contour perception in Parkinson’s disease. J Neurol Transm. 1996;103(10):1195–1204.
27.
DiederichNJGoetzCGRamanRPappertEJLeurgansSPieryV. Poor visual discrimination and visual hallucinations in Parkinson’s disease. Clin Neuropharmacol. 1998;21(5):289–295.
28.
DiederichNJPieriVGoetzCG. Die optischen Halluzinationen des Parkinson-Patienten und das Charles Bonnet-Syndrom. Eine phänomenologische und phathogenetische Gegenüberstellung [in German]. Fortsch Neurol Psyciatr. 2000;68(3):129–136.
29.
BurkeW. The neural basis of Charles Bonnet hallucinations: a hypothesis. J Neurol Neurosurg Psychiary. 2002;73(5):535–541.
30.
FfytcheDHHowardRJBrammerMJDavidAWoodruffPWilliamsS. The anatomy of conscious vision: an fMRI study of visual hallucinations. Nat Neurosci. 1998;1(8):738–742.
31.
MatsuiHUdakaFTamuraA, et al.The relation between visual hallucinations and visual evoked potential in Parkinson disease. Clin Neuropharmacol. 2005;28(2):79–82.
32.
AugustinaiteSYanagawaYHeggelundP. Cortical feedback regulation of input to visual cortex: role of intrageniculate interneurons. J Physiol. 2011;589(pt 12):2961–2977.
33.
GhodratiMKhaligh-RazaviSMLehkySR. Towards building a more complex view of the lateral geniculate nucleus: recent advances in understanding its role. Prog Neurobiol. 2017;156:214–255.
34.
LeeJ-YYoonEJLeeWWKimYKLeeJYJeonB. Lateral geniculate atrophy in Parkinson’s disease with visual hallucination: a trans-synaptic degeneration?Mov Disord. 2016;31(4):547–554.
35.
YamamotoRIsekiEMurayamaN, et al.Investigation of Lewy pathology in the visual pathway of brains of dementia with Lewy bodies. J Neurol Sci. 2006;246(1-2):95–101.
36.
ErskineDTaylorJPFirbankMJ, et al.Changes to the lateral geniculate nucleus in Alzheimer’s disease but not dementia with Lewy bodies. Neuropathol Appl Neurobiol. 2016;42(4):366–376.
37.
MatsuiHNishinakaKOdaM, et al.Hypoperfusion of the visual pathway in Parkinsonian patients with visual hallucinations. Mov Disord. 2006;21(12):2140–2144. doi:10.1002/mds.21140.
38.
FirbankMJLloydJO’BrienT. The relationship between hallucinations and FDG-PET in dementia with Lewy bodies. Brain Imaging Behav. 2016;10(3):636–639. doi:10.1007/s11682-015-9434-0.
39.
BoeckerHCeballos-BaumannAOVolkDConradBForstlHHaussermannP. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch Neurol. 2007;64(7):984–988.
40.
FirbankMJParikhJMurphyN, et al.Reduced occipital GABA in Parkinson disease with visual hallucinations. Neurology. 2018:91(7);e675–e685. doi:10.1212/WNL.0000000000006007.
41.
WatanabeHSendaJKatoS, et al.Cortical and subcortical brain atrophy in Parkinson’s disease with visual hallucination. Mov Disord. 2013;28(12):1732–1736.
42.
GoodaleMAMilnerD. Separate visual pathways for perception and action. Trends Neurosci. 1992;15(1):20–25.
43.
RossionBJoyceCACottrellGWTarrMJ. Early lateralization and orientation tuning for face, word, and object processing in the visual cortex. Neuroimage. 2003;20(3):1609–1624.
44.
Ramírez-RuizBMartíM-JTlosaE, et al.Cerebral atrophy in Parkinson’s disease patients with visual hallucinations. Eur J Neurol. 2007;14(7):750–756.
45.
Ibarretxe-BilbaoNRamírez-RuizBTolosaE, et al.Hippocampal head atrophy predominance in Parkinson’s disease with hallucinations and with dementia. J Neurol. 2008;255(9):1324–1331.
46.
GoldmanJGStebbinsGTDinhV, et al.Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson’s disease with hallucinations. Brain. 2014;137(pt 3):849–859.
47.
MeppelinkAMde JongBMRenkenRLeendersKLCornelissenFWvan LaarT. Impaired visual processing preceding image recognition in Parkinson’s disease patients with visual hallucinations. Brain. 2009;132(pt 11):2980–2993.
48.
OkadaKSuyamaNOguroHYamaguchiSKobayashiS. Medication-induced hallucination and cerebral blood flow in Parkinson’s disease. J Neurol. 1999;246(5):365–368.
49.
OishiNUdakaFKameyamaMSawamotoNHashikawaKFukuyamaH. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology. 2005;65(11):1708–1715.
50.
HardingAJBroeGAHallidayGM. Visual hallucinations in Lewy body disease related to Lewy bodies in the temporal lobe. Brain. 2002;125(pt 2):391–403.
51.
HardingAJStimsonEHendersonJMHallidayGM. Clinical correlates of selective pathology in the amygdala of patients with Parkinson’s disease. Brain. 2002;125(pt 11):2431–2445.
52.
PapapetropoulosSMcCorquodaleDSGonzalezJJean-GillesLMashDC. Cortical and amygdalar Lewy body burden in Parkinson’s disease patients with visual hallucinations. Parkinsonism Relat Disord. 2006;12(4):253–256.
53.
GallagherDAParkkinenLO’SullivanSS, et al.Testing aetiological model of visual hallucinations in Parkinson’s disease. Brain. 2011;134(pt 11):3299–3309.
54.
HoutPJohnstonTHDarrT, et al.Increased 5-HT2A receptors in the temporal cortex of Parkinsonian patients with visual hallucinations. Mov Disord. 2010;25(10):1399–1408.
55.
ChengAVTFerrierINMorrisCM, et al.Cortical serotonin-S2 receptor binding in Lewy body dementia, Alzheimer’s and Parkinson’s disease. J Neurol Sci. 1991;106(1):50–55.
56.
PerryEKMarshallEKerwinJ, et al.Evidence of a monoaminergic–cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem. 1990;55(4):1454–1456.
57.
KometerMSchmidtAJänckeLVollenweiderFX. Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual evoked potentials, and visual hallucinations. J Neurosci. 2013;33(25):10544–10551.
58.
YasueIMatsunagaSKishiTFujitaKIwataN. Serotonin 2A receptor inverse agonist as a treatment for Parkinson’s disease psychosis: a systematic review and meta-analysis of serotonin 2A receptor negative modulators. J Alzheimers Dis. 2016;50(3):733–740.
59.
LiuYBengsonJHuangHMangunGRDingM. Top-down modulation of neural activity in anticipatory visual attention: control mechanisms revealed by simultaneous EEG-fMRI. Cereb Cortex. 2016;26(2):517–529.
60.
CusmanJDLoweKAZinkeWWoodmanGFSchallJD. Prefrontal control of visual distraction. Curr Biol. 2018;28(8):414–420.
61.
NelissenNStokesMNobreACRushworthMFS. Frontal and parietal cortical interactions with distributed visual representations during selective attention and action selection. J Neurosci. 2013;33(42):16443–16458.
62.
Corradi-Dell’AcquaCFinkGRWeidnerR. Selecting category specific visual information: top-down and bottom-up control of object based attention. Conscious Cogn. 2015;35:330–341.
63.
EgerEHensonRNDriverJDolanRJ. Mechanisms of top-down facilitation in perception of visual objects studied by FMRI. Cereb Cortex. 2007;17(9):2123–2133.
64.
PeyrinCMichelCMSchwartzS, et al.The neural substrates and timing of top-down processes during coarse-to-fine categorization of visual scenes: a combined fMRI and ERP study. J Cognitive Neurosci. 2010;22(12):2768–2780.
65.
GilbertCDLiW. Top-down influences on visual processing. Nat Rev Neurosci. 2013;14(5):350–363.
66.
ChiouRLambon RalphMA. The anterior temporal cortex is a primary semantic source of top-down influences on object recognition. Cortex. 2016;79:75–86.
67.
BudaMFornitoABergströmZMSimonsJS. A specific brain structural basis of individual differences in reality monitoring. J Neurosci. 2011;31(40):14308–14313.
68.
KuJKimJ-JJungYC, et al.Brain mechanisms involved in processing unreal perceptions. Neuroimage. 2008;43(4):793–800.
69.
TakahashiEOhkiKMiyashitaY. The role of the parahippocampal gyrus in source memory for external and internal events. Neuroreport. 2002;13(15):1951–1956.
70.
Stephan-OttoCSiddiSSeniorC, et al.Visual imagery and false memory of pictures: a functional magnetic resonance imaging study in healthy participants. PLoS One. 2017;12(1):e0169551. doi:10.1371/journal.pone.0169551.
71.
Sanchez-CastanedaCReneRRamirez-RuizB, et al.Frontal and associative visual areas related to visual hallucinations in dementia with Lewy bodies and Parkinson’s disease with dementia. Mov Disord. 2010;25(5):615–622.
72.
ShinSLeeJEHongJYSuwooMKSohnYHLeePH. Neuroanatomical substrates of visual hallucinations in patients with non-demented Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2012;83(12):1155–1161.
73.
Nagano-SaitoAWashimiYArahataY, et al.Visual hallucination in Parkinson’s disease with FDG PET. Mov Disord. 2004;19(7):801–806.
74.
StebbinsGTGoetzCGCarrilloMC, et al.Altered cortical visual processing in PD with hallucinations. An fMRI study. Neurology. 2004;63(8):1409–1416.
75.
Ramírez-RuizBMartíM-JTolosaE, et al.Brain response to complex visual stimuli in Parkinson’s patients with hallucinations: a functional magnetic resonance imaging study. Mov Disord. 2008;23(16):2335–2343.
76.
BarnesJBoubertLHarrisJLeeADavidAS. Reality monitoring and visual hallucinations in Parkinson’s disease. Neuropsychologia. 2003;41(5):565–574.
77.
BlankeOLandisTSeeckM. Electrical cortical stimulation of the human prefrontal cortex evokes complex visual hallucinations. Epilepsy Behav. 2000;1(5):356–361.
78.
NelsonAEGilliamFAcharyaJMirandaS. A unique patient with epilepsy with cinematographic visual hallucinations. Epilepsy Behav Case Rep. 2016;5:78–79.
79.
KataokaHFuriyaYMorikawaMUenoSInoueM. Increased temporal blood flow associated with visual hallucinations in Parkinson’s disease with dementia. Mov Disord. 2008;23(3):464–465.
80.
GoetzCGVaughanCLGoldmanJGStebbinsGT. I finally see what you see: Parkinson’s disease visual hallucinations captured with functional neuroimaging. Mov Disord. 2014;29(1):115–117.
81.
PerrettDIRollsETCaanW. Visual neurons responsive to face in the monkey temporal cortex. Exp Brain Res. 1982;47(3):329–342.
82.
HasselmoMERollsETBaylisGC. The role of expression and identity in the face-selective responses of neurons in the temporal visual cortex of the monkey. Behav Brain Res. 1989;32(3):203–218.
83.
OnofrjMThomasAD’AndreamatteoG, et al.Incidence of RBD and hallucination in patients affected by Parkinson’s disease: 8-year follow-up. Neurol Sci. 2002;23(suppl 2):S91–S94.
84.
ManniRPacchettiCTerzaghiMSartoriIManciniFNappiG.Hallucinations and sleep-wake cycle in PD: a 24-hour continuous polysomnographic study. Neurology. 2002;59(12):1979–1981.
85.
PappertEJGoetzCGNiedermanFGRamanRLeurgansS. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson’s disease. Mov Disord. 1999;14(1):117–121.
86.
PacchettiCManniRZangagliaR, et al.Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson’s disease. Mov Disord. 2005;20(11):1439–1448.
87.
PerryEKMorrisCMCourtJA, et al.Alteration in nicotine binding sites in Parkinson’s disease, Lewy bode dementia and Alzheimer’s disease: possible index of early neuropathology. Neuroscience. 1995;64(2):385–395.
88.
HeppDHRuiterAMVoornyGP, et al.Pedunculopontine cholinergic cell loss in hallucinating Parkinson disease patients but not in dementia with Lewy bodies patients. J Neuropathol Exp Neurol. 2013;72(12):1162–1170.
89.
RyeDB. Contributions of the pedunculopontine region to normal and altered REM sleep. Sleep. 1997;20(9):757–788.
90.
PerryEKIrvingDKerwinJM, et al.Cholinergic transmitter and neurotrophic activities in Lewy body dementia: similarity to Parkinson’s and distinction from Alzheimer’s disease. Alzheimer Dis Assoc Disord. 1993;7(2):69–79.
